High baseline sPD-L1 plasma levels predict shorter OS, independent of treatment with R-CHOP or R-HDT.
In this phase II study, brentuximab appeared to be safe and well tolerated by elderly patients with HL who have limited tolerance to conventional therapies and poorer prognosis than younger patients.
FCR yields higher rates of CR and MRD negativity, and longer PFS, in comparison to BR, but was associated with increased adverse events, in patients with untreated, active CLL without del(17p) and good physical fitness.
In this phase III trial, the addition of ofatumumab to chlorambucil in patients 65 years of age or older who are not suitable for fludarabine improved PFS, response rates, and extended the treatment-free period by more than 1 year compared with chlorambucil alone.
The obinutuzumab combination improved survival and clinical response rate in patients with previously untreated CLL with comorbidities vs the rituximab combination or chlorambucil alone with similar safety profiles.
In a phase II trial, a rituximab/ibrutinib regimen was well tolerated and showed high activity as measured by ORR and lymphocyte reduction.
In this phase II trial, efficacy of idelalisib was independent of previous treatment history, histologic subtype, or degree of refractory disease.
In this phase II study, high rates of PFS, EFS, and OS were seen in patients with DLBCL, regardless of cell of origin.
Response rates were similar in high-risk patients with del(17p) and fludarabine resistance.
In interim results of a phase III study, idelalisib plus rituximab improved PFS and OS vs rituximab plus placebo in a heavily pretreated population, including patients with unfavorable genetics, with an acceptable safety profile.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.